(S)-2-(1-methylpyrrolidin-2-yl)acetic acid | 137693-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-2-(1-methylpyrrolidin-2-yl)acetic acid
• 英文别名: 2-[(2S)-1-methylpyrrolidin-1-ium-2-yl]acetate
• CAS: 137693-28-8
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: WQGHBXNTZFIOSX-LURJTMIESA-N

物化性质

• 沸点：
  251.5±13.0 °C(Predicted)
• 密度：
  1.084±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2-(1-methylpyrrolidin-2-yl)acetic acid 在 sodium hydride 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.91h， 生成 (S)-N-(1-(furo[2,3-c]pyridin-7-yloxy)-2-methylpropan-2-yl)-2-(1- methylpyrrolidin-2-yl)acetamide
  参考文献：
  名称：

  [EN] N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS
  [FR] DÉRIVÉS DE N-HÉTÉROARYLALKYLE-2-(HÉTÉROCYCLYLE ET HÉTÉROCYCLYLMÉTHYLE) ACÉTAMIDE UTILISÉS EN TANT QU'AGONISTES DE SSTR4

  摘要：

  揭示了Formula 1的化合物及其药用盐，其中L、n、R1、R2、R6、R7、R8、R9、R10、X3、X4和X5在说明书中有定义。本公开还涉及制备Formula 1化合物的材料和方法，包含它们的药物组合物，以及它们用于治疗与SSTR4相关的疾病、疾患和症状的用途。

  公开号：

  WO2021202781A1
• 作为产物：
  描述：

  N-甲基-L-脯氨醇 在 盐酸 、 氯化亚砜 、 碳酸氢钠 作用下， 以 乙醇 为溶剂， 反应 5.25h， 生成 (S)-2-(1-methylpyrrolidin-2-yl)acetic acid
  参考文献：
  名称：

  Late intermediates in the biosynthesis of cocaine: 4-(1-methyl-2-pyrrolidinyl)-3-oxobutanoate and methyl ecgonine

  摘要：

  Methyl (RS)-[1,2-C-13(2),1-C-14]-4-(1-methyl-2-pyrrolidinyl)-3-oxobutanoate was synthesized from a mixture of sodium [1,2-C-13(2)]- and (1-C-14]acetate. This beta-keto ester was administered to intact Erythroxylum coca plants, resulting in the formation of labeled cocaine and methyl ecgonine. The presence of contiguous C-13 atoms in these alkaloids at C-2 and C-9 was established by C-13 NMR spectroscopy, and the presence of C-14 at C-9 was established by a chemical degradation. These results are consistent with our new hypothesis for the biosynthesis of cocaine, which involves the intermediacy of 4-(1-methyl-2-pyrrolidinyl)-3-oxobutanoate (rather than 2-(1-methyl-2-pyrrolidinyl)-3-oxobutanoate) in the formation of the tropane moiety of cocaine. Support for this biogenetic scheme was also obtained by a biomimetic synthesis of 2-carbomethoxy-3-tropinone by the oxidation of methyl 4-(1-methyl-2-pyrrolidinyl)-3-oxobutanoate with mercuric acetate. The formation of labeled cocaine and methyl ecgonine in leaf cuttings of Erythroxylum coca was observed after incubation with. [9-C-14]-2-carbomethoxy-3-tropinone. The degree of incorporation of this precursor into cocaine was significantly increased by the concomitant administration of the N-acetylcysteamine thioester of benzoic acid, with a corresponding reduction in the degree of incorporation into methyl ecgonine.

  DOI：

  10.1021/ja00024a039

文献信息

• [EN] TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION<br/>[FR] ANALOGUES DE LA TUBULYSINE ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：PFIZER

  公开号：WO2017134547A1

  公开（公告）日：2017-08-10

  The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

  本发明涉及新的细胞毒性的管素类似物和衍生物，以及它们的抗体药物偶联物，以及使用它们治疗包括癌症在内的医疗状况的方法。
• Effective Methods for the Synthesis ofN-Methylβ-Amino Acids from All Twenty Commonα-Amino Acids Using 1,3-Oxazolidin-5-ones and 1,3-Oxazinan-6-ones
  作者：Andrew B. Hughes、Brad E. Sleebs

  DOI：10.1002/hlca.200690235

  日期：2006.11

  N-Methyl β-amino acids are generally required for application in the synthesis of potentially bioactive modified peptides and other oligomers. Previous work highlighted the reductive cleavage of 1,3-oxazolidin-5-ones to synthesise N-methyl α-amino acids. Starting from α-amino acids, two approaches were used to prepare the corresponding N-methyl β-amino acids. First, α-amino acids were converted to

  应用N-甲基β-氨基酸通常是潜在合成具有生物活性的修饰的肽和其他寡聚体的应用。先前的工作强调了1，3-恶唑烷-5-酮的还原裂解以合成N-甲基α-氨基酸。从α-氨基酸开始，使用两种方法来制备相应的N-甲基β-氨基酸。首先，α -氨基酸转化为Ñ甲基α -氨基酸由所谓的“-1,3-恶唑-5-酮的策略”，将它们再由同系阿恩特-艾斯特方法，得到Ñ-protected Ñ -甲基β -氨基酸选自20种常见衍生α -氨基酸。这些化合物的制备产率为23–57％（相对于N-甲基α-氨基酸）。在第二种方法中，可以通过Arndt–Eistert方法将12个N保护的α-氨基酸直接同源，然后将所得的β-氨基酸以30–45％的产率转化为1,3-恶二嗪-6-酮。 。最后，还原裂解以41–63％的收率提供了所需的N-甲基β-氨基酸。
• Quinazoline Derivatives
  申请人：Hennequin Laurent Francois Andre

  公开号：US20080234263A1

  公开（公告）日：2008-09-25

  The invention concerns quinazoline derivatives of Formula (I) wherein each of R 1 , R 3 , R 20 , X 1 , X 2 , Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of turnours which are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

  本发明涉及公式(I)的喹嗪衍生物，其中R1、R3、R20、X1、X2、Z、W、(a)和(q)中的每一个具有在说明书中定义的任何含义；制备它们的过程，包含它们的制药组合物以及它们在制造用作抗增殖剂的药物中的用途，用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤，特别是EGFR酪氨酸激酶。
• Triazolo-pyrimidine compounds and uses thereof
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US10858365B2

  公开（公告）日：2020-12-08

  The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

  本公开涉及靶向腺苷受体（尤其是A1和A2，特别是A2a）的新型三唑并嘧啶化合物。本公开还涉及包含一种或多种化合物作为活性成分的药物组合物，以及这些化合物在治疗腺苷受体（AR）相关疾病中的用途，例如癌症，如NSCLC、RCC、前列腺癌和乳腺癌。
• WO2020052631A5
  申请人：——

  公开号：WO2020052631A5

  公开（公告）日：2022-09-05